Trials / Completed
CompletedNCT02079324
Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer
A Single Center, Open-Label, Accelerated Titration, Dose-Escalating, Phase Ι Study to Evaluate the Safety and Tolerability of IT Injection GX-051, Stem Cell Based Gene Therapeutics in Patients With Very Advanced Head and Neck Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Genexine, Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to evaluate MTD, Safety and efficacy of GX-051 after intratumoral injection in head and neck cancer patience.
Detailed description
The primary purpose of the study is to determine MTD(Maximum Tolerable Dose) of GX-051 administered in tumor. The second purpose is to evaluate safety and efficacy of GX-051.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GX-051 | intratumoral injection |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2014-03-05
- Last updated
- 2025-08-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02079324. Inclusion in this directory is not an endorsement.